{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:59:07Z","timestamp":1771297147284,"version":"3.50.1"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1097\/gco.0000000000000042","type":"journal-article","created":{"date-parts":[[2014,6,29]],"date-time":"2014-06-29T21:48:06Z","timestamp":1404078486000},"page":"314-321","source":"Crossref","is-referenced-by-count":41,"title":["Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer"],"prefix":"10.1097","volume":"26","author":[{"given":"Ramez N.","family":"Eskander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-15-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-15-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014.","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R3-15-20210129","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.6004\/jnccn.2010.0104","article-title":"Cervical Cancer.","volume":"8","author":"Greer","year":"2010","journal-title":"J Nat Comprehensive Cancer Net"},{"key":"R4-15-20210129","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1097-0142(19810815)48:4<899::AID-CNCR2820480406>3.0.CO;2-6","article-title":"Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.","volume":"48","author":"Thigpen","year":"1981","journal-title":"Cancer"},{"key":"R5-15-20210129","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1985.3.8.1079","article-title":"Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.","volume":"3","author":"Bonomi","year":"1985","journal-title":"J Clin Oncol"},{"key":"R6-15-20210129","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.1989.7.10.1462","article-title":"3rd, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.","volume":"7","author":"McGuire","year":"1989","journal-title":"J Clin Oncol"},{"key":"R7-15-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0090-8258(03)00253-1","article-title":"Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.","volume":"90","author":"Fracasso","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R8-15-20210129","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1006\/gyno.1995.1157","article-title":"Phase II trial of mitomycin-C in squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study.","volume":"57","author":"Thigpen","year":"1995","journal-title":"Gynecol Oncol"},{"key":"R9-15-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00173765","article-title":"Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study.","volume":"7","author":"Sutton","year":"1989","journal-title":"Invest New Drugs"},{"key":"R10-15-20210129","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/gyno.1998.5129","article-title":"A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study.","volume":"70","author":"Look","year":"1998","journal-title":"Gynecol Oncol"},{"key":"R11-15-20210129","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/gyno.1999.5671","article-title":"Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group.","volume":"76","author":"Schilder","year":"2000","journal-title":"Gynecol Oncol"},{"key":"R12-15-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/gyno.2000.5807","article-title":"Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.","volume":"77","author":"Bookman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"R13-15-20210129","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2001.19.5.1275","article-title":"Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study.","volume":"19","author":"Curtin","year":"2001","journal-title":"J Clin Oncol"},{"key":"R14-15-20210129","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.1996.14.3.792","article-title":"Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.","volume":"14","author":"McGuire","year":"1996","journal-title":"J Clin Oncol"},{"key":"R15-15-20210129","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COC.0b013e31803377c8","article-title":"Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.","volume":"30","author":"Garcia","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"R16-15-20210129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ygyno.2004.09.028","article-title":"Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.","volume":"96","author":"Muggia","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R17-15-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11912-005-0007-z","article-title":"Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer.","volume":"7","author":"Tewari","year":"2005","journal-title":"Curr Oncol Rep"},{"key":"R18-15-20210129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1997.15.1.165","article-title":"Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.","volume":"15","author":"Omura","year":"1997","journal-title":"J Clin Oncol"},{"key":"R19-15-20210129","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.2002.07.045","article-title":"Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.","volume":"20","author":"Bloss","year":"2002","journal-title":"J Clin Oncol"},{"key":"R20-15-20210129","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.","volume":"22","author":"Moore","year":"2004","journal-title":"J Clin Oncol"},{"key":"R21-15-20210129","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.","volume":"23","author":"Long","year":"2005","journal-title":"J Clin Oncol"},{"key":"R22-15-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/gyno.2000.6024","article-title":"A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.","volume":"81","author":"Muderspach","year":"2001","journal-title":"Gynecol Oncol"},{"key":"R23-15-20210129","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2391::AID-CNCR14>3.0.CO;2-M","article-title":"A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix.","volume":"79","author":"Papadimitriou","year":"1997","journal-title":"Cancer"},{"key":"R24-15-20210129","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2005.10.522","article-title":"3rd. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.","volume":"23","author":"Monk","year":"2005","journal-title":"J Clin Oncol"},{"key":"R25-15-20210129","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.","volume":"27","author":"Monk","year":"2009","journal-title":"J Clin Oncol"},{"key":"R26-15-20210129","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2010.08.020","article-title":"Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.","volume":"119","author":"Cella","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R27-15-20210129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jjco\/hyp117","article-title":"A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study GroupJapan Clinical Oncology Group Study (JCOG0505).","volume":"40","author":"Saito","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"R28-15-20210129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2009.09.006","article-title":"Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R29-15-20210129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.seminoncol.2008.12.008","article-title":"Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.","volume":"36","author":"Tewari","year":"2009","journal-title":"Semin Oncol"},{"key":"R30-15-20210129","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"R31-15-20210129","first-page":"108","article-title":"The rationale for the use of nonplatinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.","volume":"8","author":"Tewari","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"R32-15-20210129","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1159\/000232385","article-title":"Beyond platinum for metastatic and recurrent carcinoma of the cervix.","volume":"32","author":"Tewari","year":"2009","journal-title":"Onkologie"},{"key":"R33-15-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2011.06.001","article-title":"SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.","volume":"123","author":"Symonds","year":"2011","journal-title":"Gynecol Oncol"},{"key":"R34-15-20210129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s002800100327","article-title":"Synergistic interaction between topotecan and microtubule-interfering agents.","volume":"48","author":"Bahadori","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"R35-15-20210129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00280-004-0814-1","article-title":"Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase III study.","volume":"54","author":"Stathopoulos","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"R36-15-20210129","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2003.11.019","article-title":"Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.","volume":"92","author":"Tiersten","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R37-15-20210129","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1634\/theoncologist.8-1-76","article-title":"Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.","volume":"8","author":"West","year":"2003","journal-title":"Oncologist"},{"key":"R38-15-20210129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"3rd, et al. Improved survival with bevacizumab in advanced cervical cancer.","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GCO.0000000000000042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:41:44Z","timestamp":1620952904000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001703-201408000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/gco.0000000000000042","relation":{},"ISSN":["1040-872X"],"issn-type":[{"value":"1040-872X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}